SEC Form 4 · accession 0001477932-18-004696
Nascent Biotech Inc. · NBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lowell Thomas Holden
Officer — CFO · Director
Period of report
Jun 28, 2018
Accepted (ET)
Oct 2, 2018 · 11:53 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001622057
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 28, 2018 | J | 23,942 | $0.50 | A | 956,485 | D | |
| Common Stock | Sep 28, 2018 | J | 59,683 | $0.19 | A | 1,016,172 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were granted as part of the employment contract with the Company.